The 2026 Bundibugyo Ebola outbreak exposed the limits of single-strain vaccine strategies. Discuss the need for a pan-filovirus R&D approach and India's possible role in it.

Several related viruses cause Ebola disease, but the only licensed vaccine, Ervebo, targets just one of them: the Zaire Ebola virus [1]. The 2026 DRC outbreak was caused by the Bundibugyo virus, for which no approved vaccine or treatment existed [2]. This shows that filovirus R&D cannot keep betting on a single strain.

Limits of the single-strain strategy

• No product ready: there are no approved vaccines or therapeutics for Bundibugyo or Sudan virus disease [2].
• Unclear cross-protection: WHO experts called the evidence that Ervebo protects against Bundibugyo "limited and inconclusive" [3]. WHO's August guidance said Ervebo should be used only within research protocols [4].
• Months lost: the leading rVSV Bundibugyo candidate needed 7–9 months before it could enter a trial [3]. The Tumaini Phase 2/3 trial began only on 23 October 2026. By then the DRC had recorded 4,687 deaths, a crude fatality ratio of 48.3% [5].
• Late safety trials: Phase 1 testing of a Bundibugyo candidate began in the UK only on 24 July [6].

Why a pan-filovirus R&D approach is needed

• Broad platforms: multivalent vaccines, or adaptable vector platforms (rVSV, ChAdOx1), could cover Zaire, Sudan, Bundibugyo and Marburg viruses.
• Trials ready before outbreaks: WHO already has CORE trial protocols [2]. Pre-approved protocols, animal data and trial batches could cut months from the next response.
• Medicines that work across species: WHO recommends oral obeldesivir for contacts after exposure, before they fall ill [3]. Antivirals like this depend less on the exact strain.
• Steady funding: WHO calls for coordinated investment in Bundibugyo vaccines and treatments [3], but the response still faces critical funding gaps [5].

India's possible role

• Manufacturing scale: the Serum Institute of India is co-developing ChAdOx1 Bundibugyo with Oxford, which could be ready for efficacy trials in 2–3 months [3]. India can supply affordable doses quickly when demand surges.
• Research base: the BSL-4 lab at ICMR-NIV Pune can support work on the virus and on animal studies.
• Health diplomacy: experience from Vaccine Maitri and India–Africa partnerships can help build trial sites and drug-regulation capacity in Africa.
• Preparedness at home: strengthen screening at points of entry and avoid travel bans, as WHO advises [5].

Bundibugyo shows that a vaccine built for one strain fails when a related virus causes the outbreak. A pan-filovirus approach would combine broad platforms, trials prepared in advance and pooled financing. With its manufacturing scale and research base, India can help move global preparedness from reacting to outbreaks to preparing for them, in line with SDG 3.b on vaccine R&D and access.